{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:17:11Z","timestamp":1787023031181,"version":"build-2736575974"},"reference-count":97,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2009,4,1]]},"DOI":"10.1586\/erv.09.15","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T11:29:21Z","timestamp":1239017361000},"page":"401-423","source":"Crossref","is-referenced-by-count":58,"title":["Current status and progress of prepandemic and pandemic influenza vaccine development"],"prefix":"10.1586","volume":"8","author":[{"given":"Isabel","family":"Leroux-Roels","sequence":"first","affiliation":[{"name":"Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, 9000, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.05-0979"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1126\/science.1115717"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1038\/nature04017"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1038\/nature04795"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706849105"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068205"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1038\/nri2054"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.05.033"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00509-1"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-002-0146-x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(06)70528-X"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.12.005"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69340-9"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.4161\/hv.2.1.2554"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.050"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.7.2.241"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1086\/590913"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030040"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70232-9"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.046"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60627-3"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-06"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro979"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05066-2"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.937-943.1999"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00632-1"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.02.019"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.02.039"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.006"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.05.013"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00301-0"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073121"},{"key":"CIT0033","unstructured":"Barrett N. Vero cell technology and H5N1 influenza vaccines \u2013 a unique combination. Presented at:\n                      13th International Congress on Infectious Diseases\n                      . Kuala Lumpur, Malaysia, 19\u201322 June 2008."},{"key":"CIT0034","unstructured":"Kistner O, Howard MK, Sabarth N\n                      et al.\n                      Induction of cross-clade anti-H5N1 immune responses in mice, guinea pigs and ferrets by Vero cell-derived H5N1 whole virus candidate vaccine. Presented at:\n                      Third European Influenza Conference \u2013 ESWI\n                      . Vilamoura, Portugal, 14\u201317 September 2008."},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.077"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.046"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.02.029"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-002-0147-9"},{"key":"CIT0039","unstructured":"Hehme N, Kuhn A, Mueller M\n                      et al.\n                      Whole virus alum-adjuvanted pandemic vaccine: safety and immunogenicity data on a vaccine formulated with H5N1. Presented at:\n                      International Conference on Influenza Vaccines for the World \u2013 IVW2006\n                      . Vienna, Austria, 18\u201320 October 2006."},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61297-5"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.02.068"},{"key":"CIT0042","unstructured":"Chu D-S, Dram\u00e9 M, Hwang S-J. Safety and immunogenicity of an AS adjuvanted H5N1 pepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Presented at:\n                      Xth International Symposium on Respiratory Viral Infections\n                      . Singapore, 28 February\u20131 March 2008 (Abstract)."},{"key":"CIT0043","doi-asserted-by":"crossref","unstructured":"Ballester A, Garc\u00e9s-Sanches M, Planelles Cantinaro M. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 6\u20139 years. A Phase II study. Presented at:\n                      26th Annual Meeting of the European Society for Pediatric Infectious Diseases\n                      . Graz, Austria, 13\u201317 May 2008.","DOI":"10.1016\/j.ijid.2008.05.364"},{"key":"CIT0044","doi-asserted-by":"crossref","unstructured":"Ballester A, Garc\u00e9s-Sanches M, Planelles Cantinaro M\n                      et al.\n                      Pediatric safety evalation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3\u20139 years. A Phase II study. Presented at:\n                      13th International Congress of Infectious Diseases\n                      . Kuala Lumpur, Malaysia, 19\u201322 June 2008.","DOI":"10.1016\/j.ijid.2008.05.364"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200822050-00001"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001665"},{"key":"CIT0047","doi-asserted-by":"crossref","unstructured":"Leroux-Roels I, Moris P, Dram\u00e9 M\n                      et al.\n                      Persistent immune response against clade 1 and 2 H5N1 strains induced by an AS adjuvanted H5N1 clade 1 candidate prepandemic influenza vaccine. Presented at:\n                      International Conference on Avian Influenza\n                      . Bangkok, Thailand, 23\u201325 January 2008.","DOI":"10.1371\/journal.pone.0001665"},{"key":"CIT0048","unstructured":"Moris P, Leroux-Roels I, Dram\u00e9 M\n                      et al.\n                      Heterologous cell-mediated immunity priming using adjuvanted H5N1 vaccine. Presented at:\n                      IXth International Symposium on Respiratory Viral Infections\n                      . Hong Kong, China, 3\u20136 March 2007."},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.9.4420-4429.2002"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.4.2191-2198.2005"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1086\/505229"},{"key":"CIT0052","unstructured":"Baras B, Stittelaar K, Simon JH. Immunization with low dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge. Presented at:\n                      IXth International Symposium on Respiratory Viral Infections\n                      . Hong Kong, China, 3\u20136 March, 2007."},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001401"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.3201\/eid1305.061248"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181861dd7"},{"key":"CIT0056","author":"Fazekas","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1006\/biol.1997.0086"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1086\/428948"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1086\/508174"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1086\/527489"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805274"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2.2.197"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.5.699"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.6.5.659"},{"key":"CIT0065","unstructured":"Borgogni E, Castellino F, Galli G\n                      et al.\n                      MF59-adjuvanted H5N1 subunit vaccine induces a high frequency of Th1 effector\/memory CD4 T-cells which persist over time. Presented at:\n                      3rd European Influenza Conference\n                      . Vilamoura, Portugal, 14\u201317 September 2008."},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004384"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055778"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68656-X"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1086\/590913"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2000.0245"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2007.00033.x"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004028"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01928-07"},{"key":"CIT0074","unstructured":"Bigger J, Ruat C, Vasconcelos D, Legastelois I, Stark G, Caillet C. A new adjuvanted low-dose candidate pandemic influenza A(H5N1) vaccine protects ferrets against homologous clade 1 viral challenge and induces clade 2 cross-reactive antibodies. Presented at:\n                      International Conference on Avian Influenza\n                      . Bangkok, Thailand, 23\u201325 January 2008."},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69294-5"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1086\/595832"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003933"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.14.1577"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.3201\/eid1204.051020"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1038\/13484"},{"key":"CIT0081","unstructured":"WHO. Responding to the avian influenza pandemic threat: recommended strategic actions www.who.int\/csr\/resources\/publications\/influenza\/who_cds_csr_gip_05_8-en.pdf"},{"key":"CIT0082","doi-asserted-by":"crossref","unstructured":"WHO. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1; conference summary) www.cdc.gov\/eid\/content\/14\/7\/e1.htm","DOI":"10.3201\/eid1407.071681"},{"key":"CIT0083","unstructured":"WHO. Cumulative number of confirmed human cases of avian influenza A\/(H5N1) reported to WHO www.who.int\/csr\/disease\/avian_influenza\/country\/cases_table_2009_02_18\/en\/index.html"},{"key":"CIT0084","unstructured":"WHO. WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics www.who.int\/csr\/resources\/publications\/influenza\/who_cds_csr_gip_2005_5\/"},{"key":"CIT0085","unstructured":"WHO. Epidemic and pandemic alert and response www.who.int\/csr\/disease\/avian_influenza\/en\/"},{"key":"CIT0086","unstructured":"WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines www.who.int\/csr\/disease\/avian_influenza\/guidelines\/h5n1virus\/en\/index.html"},{"key":"CIT0087","unstructured":"EMEA. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP\/VEG\/4717\/03) www.emea.europa.eu\/pdfs\/human\/vwp\/471703en.pdf"},{"key":"CIT0088","unstructured":"US FDA. Guidance for industry. Clinical data needed to support the licensure of pandemic influenza vaccines www.fda.gov\/cber\/gdlns\/panfluvac.htm"},{"key":"CIT0089","unstructured":"International Federation of Pharmaceutical Manufacturers. R&D for avian\/pandemic influenza vaccines by IFPMA Influenza Vaccine Supply International Task Force (IVS ITF) members www.ifpma.org\/Influenza\/content\/pdfs\/table_avian_pandemic_influenza_vaccine_rnd_24jan06.pdf"},{"key":"CIT0090","unstructured":"International Federation of Pharmaceutical Manufacturers. About clinical trials conducted by the members of the IFPMA & IFPMA Influenza Vaccine Supply International Task Force (IVS ITF) www.ifpma.org\/influenza\/content\/pdfs\/table_H5N1_pandemic_influenza_rnd_26may08.pdf"},{"key":"CIT0091","unstructured":"WHO. Tables on the clinical trials of pandemic influenza prototype vaccines www.who.int\/vaccine_research\/diseases\/influenza\/flu_trials_tables\/en\/"},{"key":"CIT0092","unstructured":"European Medicines Agency. Committee for medicinal products for human use. Summary of positive opinion for celvapan www.emea.europa.eu\/pdfs\/human\/opinion\/celvapan_65700508en.pdf"},{"key":"CIT0093","unstructured":"US NIH. ClinicalTrials.gov database www.clinicaltrials.gov\/ct2\/results?term=baxter+and+H5N1+vaccine"},{"key":"CIT0094","unstructured":"European Medicines Agency. European Medicines Agency adopts first positive opinion for mock-up pandemic influenza vaccine www.emea.europa.eu\/pdfs\/general\/direct\/pr\/50287306en.pdf"},{"key":"CIT0095","unstructured":"European Medicines Agency. Withdrawal assessment report for aflunov www.emea.europa.eu\/humandocs\/pdfs\/epar\/aflunov\/H-804-AR-en.pdf"},{"key":"CIT0096","unstructured":"European Medicines Agency. European public assessment report for daronrix www.emea.europa.eu\/humandocs\/humans\/epar\/daronrix\/daronrix.htm"},{"key":"CIT0097","unstructured":"European Medicines Agency. European public assessment report for focetria www.emea.europa.eu\/humandocs\/humans\/epar\/focetria\/focetria.htm"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/erv.09.15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:25:55Z","timestamp":1669047955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/erv.09.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"alternative-id":["10.1586\/erv.09.15"],"URL":"https:\/\/doi.org\/10.1586\/erv.09.15","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}